Hypertriglyceridemia and the fibrate trials

Current Opinion in Lipidology

Volumn 11, Issue 6, 2000, Pages 609-614

  Faergeman, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CELL NUCLEUS RECEPTOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOGENESIS;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FEMALE; GEMFIBROZIL; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; RISK; TRIGLYCERIDES;

EID: 0033668581     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200012000-00007     Document Type: Review

References (21)

1. Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease
2. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipopretein cholesterol level: A meta-analysis of population-based prospective studies
3. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
4. The triglyceride issue revisited. Findings from the Helsinki Heart Study
5. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study
6. Myocardial infarction in the familial forms of hypertriglyceridemia
7. The vascular endothelial barrier: Selective retention of lipoproteins
8. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
9. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease
10. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
11. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal investigators
12. Systematic review on the risk and benefit of different cholesterol-lowering interventions
13. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-cholesterol
14. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
15. Pioneer research in Britain into atherosclerosis and coronary heart disease: An historical review
16. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
17. Treating patients with hypertriglyceridaemia saves lives: Triglyceride revisited
18. Secondary prevention of coronary heart disease. The role of fibric acids
19. Fibrates, dyslipoproteinaemia and cardiovascular disease
20. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease